Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TRANSFORM: A 24-week, Randomized, Placebo-controlled, Double-blind, Phase 2b Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness

NCT05014672 is registered in ClinicalTrials.gov with Calliditas Therapeutics Suisse SA as lead sponsor.

NCT NCT05014672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05014672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TRANSFORM: A 24-week, Randomized, Placebo-controlled, Double-blind, Phase 2b Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness
Lead sponsor
Calliditas Therapeutics Suisse SA
Phase
Phase 2
Overall status
Completed
Start date
February 14, 2022
Completion date
July 2, 2024
Enrollment
76 (actual)
Sites
128

Conditions

As the registry lists them; a condition with its own page is linked.

liver stiffness, primary biliary cholangitis